McKesson Corporation (MCK) rises on deep earnings beat
McKesson Corporation (MCK) rose after beating EPS and revenue estimates, but the real story goes beyond the headline. This deep-dive examines segment drivers, guidance, cash flow, shareholder returns, and the Medical-Surgical separation to show why the quarter strengthened the forward outlook.
McKesson Corporation (MCK) delivered a clean earnings and revenue beat, with EPS of $9.93 versus $9.56 expected and revenue of $105.38 billion versus $103.88 billion. Shares rose 5.91% as investors responded to stronger specialty-driven operating performance and fiscal 2027 adjusted EPS guidance of $43.80 to $44.60. The update reinforces McKesson’s earnings power, cash generation, and ongoing growth beyond core pharmaceutical distribution.
McKesson Corporation (MCK) beat earnings and revenue estimates, posting EPS of $9.93 versus $9.56 expected and revenue of $105.38B versus $103.88B. MCK rises 5.91% to $879.48 in the latest regular-session close, while fiscal 2027 adjusted EPS guidance of $43.80 to $44.60 adds support to the forward outlook.
McKesson Corporation (MCK) rises after earnings beat
Key Takeaways
MCK beat both headline estimates, with EPS of $9.93 against $9.56 expected and revenue of $105.38B against $103.88B.
Oncology and Multispecialty and Prescription Technology Solutions drove the adjusted operating income beat, according to TD Cowen.
McKesson guided to fiscal 2027 adjusted EPS of $43.80 to $44.60.
CEO Brian Tyler highlighted 18% fiscal 2026 adjusted EPS growth, $6.2B in operating cash flow, and $5.1B returned to shareholders.
The planned Medical-Surgical Solutions separation advanced through $2B of financing transactions and a proposed $1.25B Apollo minority investment.
TD Cowen raised its price target to $1,012 from $1,000 and kept a Buy rating, while Evercore ISI cut its target to $950 from $1,000 and maintained Outperform.
The central MCK earnings result was a clean top-line and bottom-line beat. EPS reached $9.93, above the $9.56 estimate. Revenue reached $105.38B, ahead of the $103.88B consensus. That combination matters because distribution companies often operate on thin margins, making small changes in volume, pricing, and mix important to earnings.
Revenue for the period ended June 30, 2026 rose from $96.30B in the March quarter. It remained below the $106.16B recorded in the December quarter. Net income was $0.61B, compared with $1.68B in March and $1.19B in December. The figures show why investors need to separate the headline EPS measure from reported net income when assessing the quarter.
The earnings surprise history adds useful perspective. EPS was $11.69 in May, $9.34 in February, $9.86 in November, and $8.26 in August 2025. The latest $9.93 result therefore fell below the immediately prior quarter, but it exceeded the February, November, and year-earlier figures listed in the earnings history.
Segment reporting also changed as McKesson introduced new operating categories. For the fiscal year ended March 31, 2026, the revenue data lists $336.652B for North American Pharmaceutical, $48.423B for Oncology and Multispecialty, $11.507B for Medical-Surgical Solutions, and $5.805B for Prescription Technology Solutions. A $1.043B reconciling item was listed outside those segments.
North American Pharmaceutical remains the largest part of the business by revenue. However, the growth narrative now extends well beyond drug distribution. McKesson added more than 570 providers to the U.S. Oncology Network in fiscal 2026. PRISM Vision increased its provider count by about 20% over the same period. These platforms give the company additional exposure to specialty care, provider services, and data products.
Prescription Technology Solutions also has a strong operating role in the story. McKesson supported 3.4 million patients during its latest annual verification season. The company said each full-time employee supported 120 more patients than in the prior year. It also helped patients save about $10B on brand and specialty medications and prevented an estimated 12 million prescriptions from being abandoned because of affordability challenges.
North American distribution faced a pricing headwind from branded pharmaceutical price changes tied to the Inflation Reduction Act. Tyler said the changes affected revenue growth, while adjusted segment operating profit still grew by double digits in fiscal 2026. That contrast points to the value of tracking profit growth and service economics rather than revenue alone.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
MCK closed at $879.48, up 5.91%. Volume was 924,761 shares, below the listed average of 1,197,965. The price move still marked a strong reaction to the earnings beat and fiscal 2027 guidance, even though trading activity was lighter than the average session.
The broader analyst view remains constructive. The consensus includes 1 strong buy, 24 buys, and 6 holds, with no sell or strong sell ratings. That distribution gives MCK a consensus Buy rating, but the target changes show a more selective debate beneath the headline optimism.
TD Cowen took the bullish side. The firm raised its price target to $1,012 from $1,000 and retained Buy. Its note credited Oncology and Manufacturer Solutions and Prescription Technology Solutions with driving an adjusted operating income beat. TD Cowen also cited stable utilization and continued specialty growth as positives.
Evercore ISI offered a more cautious reading without turning negative. It reduced its target to $950 from $1,000 and maintained Outperform. The firm focused on Prescription Technology Solutions, where more than half of GLP-1 prescription growth consists of cash-pay transactions. Evercore also flagged $70M from Norway operations, about $51M in one-time gains in Oncology and Medical during the second quarter, and roughly $15M in venture gains as items that should not be carried forward.
The two analyst actions frame the investment debate clearly. TD Cowen sees durable specialty and segment momentum. Evercore accepts the operating strength but questions how much of fiscal 2026 earnings momentum is repeatable. Neither firm changed its rating in the cited actions.
Management Commentary: Strategy, Specialty Care, and Guidance
CEO Brian Tyler described the year as a period of execution, portfolio focus, and operating momentum. His strategy has three visible parts: expand specialty platforms, build technology-enabled services, and simplify the corporate portfolio through separation.
"Earlier today, we reported a good fourth quarter that caps a year of strong performance." - Brian Tyler, CEO, Earnings Call
Tyler connected that performance to fiscal 2026 adjusted EPS growth of 18%. He also cited $6.2B in operating cash flow and $5.1B returned to shareholders. Those figures support a capital allocation story built on both internal investment and shareholder returns.
"Looking ahead, we anticipate adjusted earnings per diluted share to be in the range of $43.80 to $44.60 in fiscal '27." - Brian Tyler, CEO, Earnings Call
The Medical-Surgical Solutions separation is the largest portfolio action. McKesson completed a $1B senior secured Term Loan A and a $1B revolving credit facility for the business. It also agreed to a $1.25B investment from Apollo Funds for an approximately 13% minority interest, valuing the business at about $13B of total enterprise value. McKesson will retain operating control and majority ownership.
"As expected, there was an impact to revenue growth, but the fundamentals of our business and the strength of our value proposition to manufacturers remain very strong." - Brian Tyler, CEO, Earnings Call
That comment places the policy pressure in plain English. Branded drug price changes affect the top line, but McKesson argues that its distribution scale and manufacturer services still protect the profit engine. The company connects about 50,000 pharmacies and more than 1 million providers, while supporting more than 650 biopharma brands.
Technology is another part of the operating case. McKesson said AI-driven inventory planning contributed meaningfully to fiscal 2026 operating cash flow. Its Montreal distribution center also uses advanced storage and retrieval technology powered by AI and robots. In oncology, Ambient Scribe technology was used by more than 1,900 providers.
Bottom Line
MCK earnings delivered the combination investors wanted: an EPS beat, a revenue beat, and fiscal 2027 adjusted EPS guidance of $43.80 to $44.60. The next phase rests on specialty growth, Prescription Technology Solutions, and the Medical-Surgical Solutions separation. TD Cowen's higher target supports the growth case, while Evercore's lower target keeps attention on the repeatability of recent gains.
Yes. McKesson reported EPS of $9.93, above the $9.56 consensus estimate, and revenue of $105.38 billion versus $103.88 billion expected. The beat was driven by strength in Oncology, Multispecialty, and Prescription Technology Solutions.
+Why did McKesson stock rise after earnings?
MCK rose 5.91% to $879.48 after the company posted a top-line and bottom-line beat and raised confidence with fiscal 2027 adjusted EPS guidance of $43.80 to $44.60. Investors also reacted to management’s comments on 18% fiscal 2026 adjusted EPS growth, $6.2 billion in operating cash flow, and $5.1 billion returned to shareholders.
+What is McKesson's fiscal 2027 EPS guidance?
McKesson guided to fiscal 2027 adjusted EPS of $43.80 to $44.60. That outlook supports the stock’s post-earnings move by signaling continued earnings growth beyond the latest quarter.
+What are analysts saying about McKesson (MCK) after the report?
TD Cowen raised its price target to $1,012 from $1,000 and kept a Buy rating, citing the earnings beat in Oncology and Prescription Technology Solutions. Evercore ISI lowered its target to $950 from $1,000 but maintained Outperform, while the broader consensus remains a Buy.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on MCK?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
